Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $4.7 million.

  • Catalyst Pharmaceuticals' Cash from Financing Activities rose 17790.43% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 9039.66%. This contributed to the annual value of $140.7 million for FY2024, which is 139561.57% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Cash from Financing Activities of $4.7 million as of Q3 2025, which was up 17790.43% from $872000.0 recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Cash from Financing Activities registered a high of $141.0 million during Q1 2024, and its lowest value of -$10.1 million during Q3 2023.
  • Its 5-year average for Cash from Financing Activities is $6.9 million, with a median of $149000.0 in 2023.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Cash from Financing Activities tumbled by 1039722.22% in 2021 and then soared by 9456375.84% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Cash from Financing Activities stood at -$2.5 million in 2021, then surged by 189.19% to $2.3 million in 2022, then crashed by 129.52% to -$665000.0 in 2023, then skyrocketed by 766.62% to $4.4 million in 2024, then grew by 4.99% to $4.7 million in 2025.
  • Its Cash from Financing Activities stands at $4.7 million for Q3 2025, versus $872000.0 for Q2 2025 and $3.1 million for Q1 2025.